ABNOM
References
Q-switched Nd:YAG 레이저는 오타모반 및 이와 유사한 질환을 효과적으로 치료하는 것으로 알려져 있습니다. High-fluence 1064 nm Q-switched Nd:YAG 레이저가 특이한 부위의 몽고 반점에 피부가 밝아지지 않고 얼마나 잘 작동하는지 알아보기 위한 연구를 진행했습니다. 우리는 이러한 반점이 있는 61명의 환자를 연구하여 총 70개의 병변을 검사했습니다. 병변의 절반은 레이저로 치료되었고 나머지는 비교를 위해 치료되지 않은 채로 남겨졌습니다. 우리는 멜라닌 수치를 측정하기 위해 Mexameter®라는 장치와 저울을 사용하여 결과를 평가했습니다. 환자들은 치료군에서는 평균 14개월, 관찰군에서는 18개월 동안 추적 관찰되었습니다. 연구가 끝날 무렵, 우리는 치료군과 치료받지 않은 그룹 사이의 척도 점수와 멜라닌 수치에 유의미한 차이가 있음을 발견했으며, 레이저 치료군은 더 나은 결과를 보여주었습니다. 피부 미백을 유발하지 않는 high-fluence Q-switched Nd:YAG 레이저는 이러한 특이한 몽고 반점을 치료하는 데 효과적이고 안전한 것으로 입증되었습니다.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
The Q-switched Nd:YAG laser is known to effectively treat nevus of Ota and similar conditions. We conducted a study to see how well a high-fluence 1064 nm Q-switched Nd:YAG laser worked on Mongolian spots in unusual areas, without causing the skin to lighten. We studied 61 patients with these spots, examining a total of 70 lesions. Half of lesions were treated with the laser, while others were left untreated for comparison. We evaluated the results using a scale and a device called a Mexameter® to measure melanin levels. Patients were followed up for an average of 14 months in the treatment group and 18 months in the observation group. At the end of the study, we found significant differences in the scale scores and melanin levels between the treated and untreated groups, with the laser-treated group showing better outcomes. The high-fluence Q-switched Nd:YAG laser, without causing skin lightening, proved effective and safe for treating these unusual Mongolian spots.
ABNOM 에 대한 특정 레이저 치료 사용의 효과와 안전성을 연구하고 어떤 요인이 효과에 영향을 미칠 수 있는지 살펴보았습니다. 우리는 ABNOM 증상이 있고 2회에서 9회 사이의 레이저 치료를 받은 110명의 환자를 살펴보았습니다. 우리는 치료 기간이 길어질수록 치료 효과가 더 좋아졌으나 노인 환자의 경우에는 그렇지 않다는 것을 발견했습니다. 또한 피부가 더 가벼우며 (III형) 영향을 받은 부위가 더 작은 (10cm2 미만) 환자에게도 더 효과적이었습니다. ABNOM 과 함께 기미가 있으면 치료 효과가 떨어집니다. 영향을 받은 부위의 색상이나 개수에는 차이가 없는 것 같습니다. 환자의 약 10%는 치료 후 더 어두운 반점이 생겼습니다. 초기 다중치료로 좋은 결과를 얻었습니다. 더 어두운 피부와 더 어두운 반점을 가진 노인 환자는 치료 후 더 어두운 반점이 생길 가능성이 더 높습니다. ABNOM 및 기미가 있는 환자의 경우 기미가 악화되지 않도록 저에너지 레이저를 사용하는 것이 좋습니다.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
To evaluate the efficacy and safety of 1064-nm Q-switched Nd:YAG laser (QSNYL) therapy for ABNOM and to identify the factors influencing the outcome. A total of 110 patients with ABNOM were retrospectively evaluated and received two-to-nine treatment sessions. The curative effect was positively correlated with the treatment time and negatively correlated with the increasing age at first treatment (p < 0.05). The curative effect was better in patients with skin type III than those with type IV ( p < 0.05) and in patients with a lesion area of less than 10 cm2 than those with a larger affected area (p < 0.05). Additionally, the treatment effect was poorer in patients with concomitant melasma (p < 0.05). The treatment effect was not significantly correlated with the lesion color or number of affected sites (p > 0.05). Eleven patients (10%) developed postinflammatory hyperpigmentation (PIH). Early and repeated QSNYL therapy achieved satisfactory results for ABNOM. The risk of PIH after laser treatment is highest among patients with older age, darker lesion color, and darker skin color. For patients with ABNOM with concurrent melasma, low-energy laser therapy is recommended to reduce the risk of melasma aggravation.
○ 치료
미백제는 거의 도움이 되지 않습니다. 기미와 달리 ABNOM은 레이저 치료로 개선할 수 있으며 재발 없이 제거할 수 있습니다. ABNOM 치료는 레이저 치료를 10~20회 시행할 수 있습니다.
#QS1064 laser